---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-25-000107"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:50:29.127293+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M

## Summary
- Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.
- Net loss $20.3M ($0.48 loss per share) vs $33.3M ($0.88) in Q2 2024.
- Gross-to-net discount ~45%; DTC campaign drove 400% web engagement and 30% more prescribers.
- Cash $381.1M; pipeline: Phase 2 TP-04 (ocular rosacea) H2 2025, TP-05 (Lyme) in 2026.
- Global expansion: Japan regulatory meetings H2 2025; EU approval expected 2027.

## SEC filing metadata
- accession: 0001819790-25-000107
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/0001819790-25-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/tars-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-25-000107
- JSON: https://secwatch.observer/filing/0001819790-25-000107.json
- Plain text: https://secwatch.observer/filing/0001819790-25-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.